Extrawell Pharmaceutical Holdings Limited

Extrawell Pharmaceutical Holdings Limited (Extrawell) is an investment holding company that operates through four business segments, namely, manufacturing, trading, gene development and oral insulin. The company operates in these segments through its subsidiaries, Changchun Extrawell Pharmaceutical Co. Ltd. (CEPL), Jilin Extrawell Changbaishan Pharmaceutical Co. Ltd. (JECPL), South Asia Pharmaceutical (China) Ltd. (SAPL), Right & Rise Ltd. and Smart Ascent Ltd. (SAL). CEPL is engaged in selling 6 major biological products, principally in immunological, cardiovascular, dermatological and antithrombotics categories. JECPL is engaged in selling and distributing 8 major products in the market which are used in the treatment of immunological, cardiovascular and pulmonary diseases. SAPL is engaged in distributing imported pharmaceuticals which focus on central nervous system, antihypertensive and dermatology categories. Right & Rise Ltd. has 19 items of diabetic related gene patent rights. SAL is focused on the development and commercialization of oral insulin product. Extrawell is headquartered in Wanchai, Hong Kong.

Street: 
Room 3409-10, 34/F
City: 
Wanchai
Federal State : 
Hong Kong Special Administrative Region of China
WebSite: 
www.extrawell.com.hk
Fax: 
852--28563139

Company Index Score

Current Index Score Historical Index Score
  • Extrawell Pharmaceutical Holdings Limited currently scores 50 % in the index.
  • Extrawell Pharmaceutical Holdings Limited is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Extrawell Pharmaceutical Holdings Limited is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets